Saturday 17 October 2026 Export AUPH’s income statement to Excel — free account

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 18.9%, EPS grew 81.3%, free cash flow grew 19.1% and total debt fell 25.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

16.51 0.22 −1.32%

Follow AUPH

Alert me

Market cap: $2.2B
P/E: 6.9×
Fwd P/E: 16.5×
Dividend yield: —
F-score: 8/9
Altman Z: 7.86
Beneish M: −0.88
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 25.14

Total sells 0.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	1	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	1	1	—

Insider Ownership 9.19%

Capital & Financial Ratios $m

Market Cap 2,230.00

Revenue 311.51

Net Income 314.11

Free Cash Flow 175.07

Net Debt (399.18)

Current Ratio 5.42

Debt/Equity 0.07

P/E ratio 6.91

Fwd P/E 16.50

P/S ratio 6.89

P/B ratio 3.49

Past 5Y EPS Growth —

This Y EPS Growth (54.40%)

Next Y EPS Growth 24.79%

Next Y revenue growth 16.27%

Next 5Y EPS Growth (11.46%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.85%

10-year low 10-year high

P/B against its own 10 years 45.96%

10-year low 10-year high

EV/Sales against its own 10 years 23.44%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	350	358	398	443
Receivables	24	37	41	41
Inventory	40	39	46	45
Other	1	1	1	1
	425	447	492	541

	2023	2024	2025	Q'26
Payables	4	5	3	2
ST’ Debt	—	—	—	—
Other	2	2	2	5
	77	98	94	100

Compound Annual Growth %

	10y	5y	3y
Sales	103.27%	41.38%	28.30%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	40.09%	7.35%	12.76%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	78	83	—	—	—
’25	62	70	73	77	283
’24	50	57	68	60	235
’23	34	41	55	45	176
’22	22	28	56	28	134
’21	1	7	15	23	46
’20	0	0	0	50	50

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	33	53	—	—	—
’25	1	44	44	46	136
’24	(19)	16	17	30	44
’23	(32)	(3)	(13)	14	(33)
’22	(47)	(28)	(15)	10	(80)
’21	(54)	(38)	(40)	(26)	(158)
’20	(23)	(22)	(28)	3	(70)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	33	53	—	—	—
’25	1	44	44	46	135
’24	(19)	16	17	30	44
’23	(32)	(3)	(13)	14	(34)
’22	(47)	(28)	(15)	10	(80)
’21	(54)	(38)	(40)	(26)	(158)
’20	(23)	(22)	(32)	2	(75)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.25	0.28	—	—	—
’25	0.16	0.16	0.23	1.53	2.07
’24	(0.07)	0.01	0.10	0.01	0.04
’23	(0.18)	(0.08)	(0.09)	(0.19)	(0.54)
’22	(0.27)	(0.25)	(0.06)	(0.18)	(0.76)
’21	(0.40)	(0.37)	(0.39)	(0.25)	(1.40)
’20	(0.23)	(0.26)	(0.28)	(0.06)	(0.87)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.42	2.09	4.52	3.52	9.83	9.72	4.07	5.31	4.71	6.55	Analyst estimates 2026–2028 Powerpack
	High	5.69	10.54	7.24	21.93	21.81	33.97	23.42	12.43	10.67	16.54
People
People	Employees	20	33	39	62	294	300	300	300	130	128
	Revenue/emp, $m	0.01	0.01	0.01	0.01	0.17	0.15	0.45	0.59	1.81	2.21
Income, $m
Income, $m	Revenue	0	0	0	0	50	46	134	176	235	283
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	97.61	95.77	91.94	87.99	88.46
	EBT	(23)	(71)	(64)	(88)	(103)	(180)	(106)	(77)	7	114
	EBT margin, %	(13,465.32)	(16,935.89)	(13,833.05)	(27,748.74)	(205.06)	(395.15)	(79.35)	(44.14)	3.17	40.33
	Net income	(23)	(71)	(64)	(88)	(103)	(181)	(108)	(78)	6	287
	Depreciation	1	1	1	1	1	3	3	12	19	19
Per share, $
Per share, $	Revenue	0.00	0.01	0.01	0.00	0.42	0.35	0.94	1.23	1.64	2.11
	Earnings	(0.66)	(0.92)	(0.76)	(0.95)	(0.87)	(1.40)	(0.76)	(0.54)	0.04	2.14
	Cash flow	(0.53)	(0.54)	(0.61)	(0.68)	(0.59)	(1.22)	(0.56)	(0.23)	0.31	1.01
	Capex	0.88	0.00	0.00	0.00	(0.05)	0.00	0.00	0.00	0.00	0.00
	Free cash flow	0.35	(0.54)	(0.61)	(0.68)	(0.64)	(1.22)	(0.56)	(0.24)	0.31	1.01
	Book value	1.02	2.15	1.33	3.21	3.44	3.70	2.86	2.64	2.64	4.33
	Shares, m	35	77	85	93	118	129	142	143	143	134
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.56	7.35
	P/S	438.51	892.47	1,248.84	5,926.62	32.69	64.88	6.29	7.13	5.46	7.57
	P/B	2.11	2.25	5.14	6.31	4.02	6.18	2.08	3.31	3.40	3.69
	EV/Sales	209.33	477.49	977.01	4,965.10	24.86	54.79	3.42	5.57	4.19	6.35
	EV/FCF	2.92	(4.85)	(8.75)	(24.79)	(16.52)	(15.81)	(5.75)	(28.58)	22.33	13.27
Cash, $m
Cash, $m	Operating cash flow	(19)	(41)	(52)	(64)	(70)	(158)	(80)	(33)	44	136
	Capex	31	0	0	0	(6)	0	0	(1)	0	0
	Free cash flow	12	(41)	(52)	(64)	(75)	(158)	(80)	(34)	44	135
Balance, $m
Balance, $m	Working capital	33	167	126	304	387	473	396	348	349	398
	Total debt	—	—	—	—	6	6	5	75	59	52
	Net debt	(40)	(173)	(126)	(306)	(392)	(460)	(384)	(275)	(300)	(346)
	Shareholders’ equity	36	166	113	299	408	479	405	378	377	581
Returns, %
Returns, %	ROA	(51.44)	(57.36)	(38.20)	(37.60)	(26.06)	(35.94)	(21.33)	(15.31)	1.05	44.11
	ROIC	0.00	0.00	0.00	0.00	(395.10)	(590.76)	(330.89)	(50.58)	(7.28)	30.35
	ROE	(83.33)	(70.20)	(46.08)	(42.99)	(29.07)	(40.81)	(24.46)	(19.92)	1.52	59.91

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.9×	16.5×	+18.87% (above 0%: growing)	+81.25% (above 0%: growing)	+19.08% (above 0%: growing)	92.12%	48.19%
HRMY Harmony Biosciences Holdings, Inc.	$2.2B	12.2×	9.4×	+30.32% (above 0%: growing)	+88.41% (above 0%: growing)	+16.53% (above 0%: growing)	75.81%	34.18%	Compare
RXRX Recursion Pharmaceuticals, Inc.	$2.2B	— (loss-making)	— (loss-making)	−60.10% (below 0%: shrinking)	n/m	−32.03% (below 0%: shrinking)	(49.82%)	(1,759.69%)	Compare
VRDN Viridian Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+278.67% (above 0%: growing)	n/m	−41.39% (below 0%: shrinking)	100.00%	(44,460.56%)	Compare
IRON Disc Medicine, Inc.	$2.2B	— (loss-making)	—	—	n/m	+7.83% (above 0%: growing)	0.00%	0.00%	Compare
FTRE Fortrea Holdings Inc.	$2.2B	— (loss-making)	— (loss-making)	−4.52% (below 0%: shrinking)	n/m	+53.15% (above 0%: growing)	20.52%	2.18%	Compare
NVAX Novavax, Inc.	$2.1B	— (loss-making)	— (loss-making)	−76.30% (below 0%: shrinking)	n/m	+42.95% (above 0%: growing)	74.87%	(96.84%)	Compare
Median of peers	$2.2B	—	—	−57.10%	—	+2.15%	47.70%	(48.42%)

All 614 Biotechnology stocks →

Aurinia Pharmaceuticals Inc (AUPH) key facts

Strength: Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
Aurinia Pharmaceuticals Inc (AUPH) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AUPH traded at $16.51, a market capitalization of $2.2 billion.
Return on equity was 59.9% and debt-to-equity 0.07.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 7.86 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.